GraniteShares Advisors LLC Invests $1.21 Million in Intuitive Surgical, Inc. (NASDAQ:ISRG)

GraniteShares Advisors LLC purchased a new position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) in the 4th quarter, Holdings Channel reports. The firm purchased 3,586 shares of the medical equipment provider’s stock, valued at approximately $1,210,000.

Several other large investors also recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in Intuitive Surgical by 0.7% during the 3rd quarter. Vanguard Group Inc. now owns 29,868,227 shares of the medical equipment provider’s stock valued at $8,730,184,000 after purchasing an additional 196,316 shares during the last quarter. Geode Capital Management LLC increased its position in Intuitive Surgical by 1.0% during the 1st quarter. Geode Capital Management LLC now owns 6,444,995 shares of the medical equipment provider’s stock worth $1,642,287,000 after buying an additional 61,659 shares during the period. Morgan Stanley increased its position in Intuitive Surgical by 29.9% during the 4th quarter. Morgan Stanley now owns 5,866,613 shares of the medical equipment provider’s stock worth $1,556,706,000 after buying an additional 1,351,002 shares during the period. Jennison Associates LLC increased its position in Intuitive Surgical by 6.4% during the 3rd quarter. Jennison Associates LLC now owns 4,585,190 shares of the medical equipment provider’s stock worth $1,340,205,000 after buying an additional 274,692 shares during the period. Finally, Invesco Ltd. increased its position in shares of Intuitive Surgical by 6.6% in the third quarter. Invesco Ltd. now owns 3,750,490 shares of the medical equipment provider’s stock worth $1,096,231,000 after purchasing an additional 232,205 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Piper Sandler raised their price target on Intuitive Surgical from $325.00 to $425.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 24th. Stifel Nicolaus raised their price target on Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a research report on Monday, April 8th. Barclays lifted their target price on Intuitive Surgical from $385.00 to $430.00 and gave the company an “overweight” rating in a research report on Thursday, January 25th. Citigroup lifted their target price on Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Finally, Wells Fargo & Company lifted their price objective on Intuitive Surgical from $363.00 to $416.00 and gave the stock an “overweight” rating in a research note on Friday, January 19th. Five research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $375.70.

Insider Transactions at Intuitive Surgical

In other Intuitive Surgical news, VP Fredrik Widman sold 5,041 shares of the stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $397.07, for a total transaction of $2,001,629.87. Following the completion of the transaction, the vice president now owns 110 shares of the company’s stock, valued at $43,677.70. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, VP Fredrik Widman sold 5,041 shares of the stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $397.07, for a total transaction of $2,001,629.87. Following the sale, the vice president now owns 110 shares of the company’s stock, valued at $43,677.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Robert Desantis sold 20,296 shares of the stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $393.80, for a total transaction of $7,992,564.80. Following the sale, the executive vice president now directly owns 5,507 shares in the company, valued at approximately $2,168,656.60. The disclosure for this sale can be found here. Insiders sold 248,418 shares of company stock valued at $95,927,097 over the last 90 days. 0.80% of the stock is currently owned by corporate insiders.

Intuitive Surgical Price Performance

NASDAQ:ISRG traded up $1.19 during trading hours on Tuesday, hitting $378.55. 1,602,973 shares of the company were exchanged, compared to its average volume of 1,636,060. The stock has a market capitalization of $134.18 billion, a price-to-earnings ratio of 75.03, a PEG ratio of 5.97 and a beta of 1.36. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $403.76. The company’s 50 day moving average price is $388.13 and its 200-day moving average price is $341.56.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Tuesday, January 23rd. The medical equipment provider reported $1.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.48 by $0.12. The firm had revenue of $1.93 billion during the quarter, compared to analysts’ expectations of $1.89 billion. Intuitive Surgical had a net margin of 25.24% and a return on equity of 13.11%. The business’s revenue was up 16.6% compared to the same quarter last year. During the same period in the previous year, the business posted $0.91 EPS. On average, equities analysts predict that Intuitive Surgical, Inc. will post 4.93 earnings per share for the current year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.